Militia Capital Partners LP Has $2.16 Million Stock Position in Medpace Holdings, Inc. $MEDP

Militia Capital Partners LP reduced its holdings in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) by 62.5% in the 3rd quarter, Holdings Channel.com reports. The institutional investor owned 4,200 shares of the company’s stock after selling 7,000 shares during the period. Medpace makes up 1.0% of Militia Capital Partners LP’s holdings, making the stock its 19th biggest holding. Militia Capital Partners LP’s holdings in Medpace were worth $2,159,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors have also bought and sold shares of MEDP. Clarkston Capital Partners LLC bought a new stake in shares of Medpace during the 2nd quarter valued at approximately $40,569,000. Cibc World Market Inc. bought a new position in Medpace in the 3rd quarter valued at approximately $5,033,000. Brighton Jones LLC boosted its position in Medpace by 160.4% in the third quarter. Brighton Jones LLC now owns 4,060 shares of the company’s stock valued at $2,087,000 after buying an additional 2,501 shares in the last quarter. Wealth Enhancement Advisory Services LLC boosted its position in Medpace by 150.0% in the third quarter. Wealth Enhancement Advisory Services LLC now owns 15,193 shares of the company’s stock valued at $8,080,000 after buying an additional 9,117 shares in the last quarter. Finally, Baillie Gifford & Co. grew its stake in shares of Medpace by 12.0% during the third quarter. Baillie Gifford & Co. now owns 584,796 shares of the company’s stock worth $300,679,000 after buying an additional 62,503 shares during the last quarter. 77.98% of the stock is owned by institutional investors and hedge funds.

Medpace Stock Performance

Shares of NASDAQ:MEDP opened at $453.64 on Tuesday. The firm has a market cap of $12.87 billion, a PE ratio of 29.65, a price-to-earnings-growth ratio of 2.16 and a beta of 1.44. The firm’s fifty day moving average is $520.96 and its 200-day moving average is $539.27. Medpace Holdings, Inc. has a 52 week low of $250.05 and a 52 week high of $628.92.

Medpace (NASDAQ:MEDP) last posted its quarterly earnings data on Monday, February 9th. The company reported $4.67 earnings per share for the quarter, beating analysts’ consensus estimates of $4.18 by $0.49. The business had revenue of $708.45 million during the quarter, compared to the consensus estimate of $689.53 million. Medpace had a return on equity of 118.82% and a net margin of 17.83%.Medpace’s quarterly revenue was up 32.0% on a year-over-year basis. During the same period in the prior year, the business posted $3.67 earnings per share. Medpace has set its FY 2026 guidance at 16.680-17.500 EPS. Sell-side analysts forecast that Medpace Holdings, Inc. will post 12.29 EPS for the current year.

Wall Street Analyst Weigh In

Several research analysts have recently issued reports on the stock. Leerink Partners lowered their price target on shares of Medpace from $575.00 to $485.00 and set a “market perform” rating for the company in a report on Wednesday, February 11th. Barclays upgraded Medpace from an “underweight” rating to an “equal weight” rating and set a $500.00 price objective on the stock in a research report on Friday, March 6th. Truist Financial lowered their target price on Medpace from $555.00 to $539.00 and set a “hold” rating for the company in a report on Wednesday, February 11th. Zacks Research lowered Medpace from a “strong-buy” rating to a “hold” rating in a research note on Monday, January 12th. Finally, TD Cowen upgraded Medpace from a “sell” rating to a “hold” rating and reduced their price target for the stock from $462.00 to $419.00 in a report on Wednesday, February 18th. Five investment analysts have rated the stock with a Buy rating, nine have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Medpace has an average rating of “Hold” and an average price target of $486.67.

About Medpace

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.